TriSalus Life Sciences is focused on developing innovative treatments for liver and pancreatic tumors by addressing significant barriers to effective immunotherapy. The company employs a transformative platform that integrates Pressure-Enabled Drug Delivery™ (PEDD™) technology with immunomodulatory therapies. This approach aims to overcome two critical challenges: the immunosuppressive environment and high intratumoral pressure that hinder the efficacy of existing treatments. By enhancing the delivery of therapeutic agents directly to the tumor site, TriSalus seeks to improve patient outcomes and enable better responses to systemic immunotherapies, such as checkpoint inhibitors.

The investigational therapeutic candidate, nelitolimod (also known as SD-101), is designed to reactivate the immune system within the tumor microenvironment, potentially leading to deeper and more durable responses to immunotherapy. TriSalus's integrated approach not only targets the unique biological and physical barriers present in liver and pancreatic cancers but also aims to optimize drug delivery by modulating pressure and flow within the tumor vasculature. This comprehensive strategy is intended to enhance the effectiveness of immunotherapeutic agents, ultimately improving the treatment landscape for patients suffering from these challenging malignancies.

United States

Developing investigational treatments to attack liver metastases and pancreatic solid tumors and stimulate the immune system by delivering a combination of immunotherapies directly to the site of disease.

TriSalus Life Sciences

Company Details